Viper 101
Alternative Names: Viper-101Latest Information Update: 03 Mar 2026
At a glance
- Originator viTToria Biotherapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma; T-cell lymphoma
Most Recent Events
- 06 Dec 2025 Efficacy, adverse event and pharmacodynamic data from a phase I trial in Non-Hodgkin's lymphoma presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
- 09 Dec 2024 Pharmacodynamics data from a preclinical trial in T-cell lymphoma released by Vittoria Biotherapeutics
- 07 Dec 2024 Pharmacodynamics data from a preclinical study in T cell Non-Hodgkin lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)